Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature
Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature
Introduction: Prostate cancer is the most common cancer amongst men in the UK. Treatments for malignant ureteric obstruction consist of percutaneous nephrostomy, ureteric stent insertion, or occasionally other forms of urinary diversion. Our aim was to look at the outcomes of percutaneous nephrostomy (PCN) in patients with advanced prostate cancer and to look at the impact on patient's general health, quality of life, life expectancy and complications after PCN insertion.
Material and methods: A systematic review of the literature was done for all prospective English language articles on PCN in patients with prostate cancer using PubMed, MEDLINE, EMBASE, Scopus, CINAHL, Cochrane library, Clinicaltrials.gov, Google Scholar and individual urological journals from inception to August 2017. While studies involving prostate cancer patients were included, studies on all other mixed pelvic malignancies were excluded.
Results: Seven articles met the inclusion criteria. There were 184 patients, with a mean age of 70 years (range: 51-94 years). PCN was performed for ureteric obstruction due to advanced prostate cancer, patients underwent unilateral (n = 66) or bilateral PCN (n = 118) with conversion to an antegrade stent in 25 patients. Their post-PCN survival varied between 4-31 months and this was longer if they were hormone naïve or showed a good recovery in their renal function. Although the complication rates were low (1-3%), patients spend a high proportion of their lives in the hospital.
Conclusions: PCNs should only be pursued after thoughtful counselling regarding further treatment options and prognosis as these patients with advanced malignancies seem to have reduced survival duration and spend a significant amount of time in hospital.
404-409
New, Francesca
a0d0c2ab-a96b-42b2-9512-26dc6ca197d2
Deverill, Sally
9cdca666-599c-4eaf-aabb-f055adf0d03f
Somani, Bhaskar K.
ab5fd1ce-02df-4b88-b25e-8ece396335d9
2018
New, Francesca
a0d0c2ab-a96b-42b2-9512-26dc6ca197d2
Deverill, Sally
9cdca666-599c-4eaf-aabb-f055adf0d03f
Somani, Bhaskar K.
ab5fd1ce-02df-4b88-b25e-8ece396335d9
New, Francesca, Deverill, Sally and Somani, Bhaskar K.
(2018)
Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature.
Central European Journal of Urology, 71 (4), .
(doi:10.5173/ceju.2018.1780).
Abstract
Introduction: Prostate cancer is the most common cancer amongst men in the UK. Treatments for malignant ureteric obstruction consist of percutaneous nephrostomy, ureteric stent insertion, or occasionally other forms of urinary diversion. Our aim was to look at the outcomes of percutaneous nephrostomy (PCN) in patients with advanced prostate cancer and to look at the impact on patient's general health, quality of life, life expectancy and complications after PCN insertion.
Material and methods: A systematic review of the literature was done for all prospective English language articles on PCN in patients with prostate cancer using PubMed, MEDLINE, EMBASE, Scopus, CINAHL, Cochrane library, Clinicaltrials.gov, Google Scholar and individual urological journals from inception to August 2017. While studies involving prostate cancer patients were included, studies on all other mixed pelvic malignancies were excluded.
Results: Seven articles met the inclusion criteria. There were 184 patients, with a mean age of 70 years (range: 51-94 years). PCN was performed for ureteric obstruction due to advanced prostate cancer, patients underwent unilateral (n = 66) or bilateral PCN (n = 118) with conversion to an antegrade stent in 25 patients. Their post-PCN survival varied between 4-31 months and this was longer if they were hormone naïve or showed a good recovery in their renal function. Although the complication rates were low (1-3%), patients spend a high proportion of their lives in the hospital.
Conclusions: PCNs should only be pursued after thoughtful counselling regarding further treatment options and prognosis as these patients with advanced malignancies seem to have reduced survival duration and spend a significant amount of time in hospital.
This record has no associated files available for download.
More information
Accepted/In Press date: 17 November 2018
e-pub ahead of print date: 29 November 2018
Published date: 2018
Identifiers
Local EPrints ID: 433336
URI: http://eprints.soton.ac.uk/id/eprint/433336
ISSN: 2080-4806
PURE UUID: 82fece88-647e-4eda-98a0-d274d7f134e4
Catalogue record
Date deposited: 14 Aug 2019 16:30
Last modified: 16 Mar 2024 03:24
Export record
Altmetrics
Contributors
Author:
Francesca New
Author:
Sally Deverill
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics